Clinical

Dataset Information

A phase lb/ll, open label, single arm study to assess efficacy and safety of alpelisib and capecitabine in patients with PIK3CA mutant metastatic colorectal cancer who failed two prior standard chemotherapies


ABSTRACT: Interventions: Drug : Alpelisib: oral administration In Phase lb, 200mg and 300mg once daily will be tested. In Phase ll, the recommended phase ll dose (RP2D) in phase lb will be used. Capecitabine: oral administration, In Phase lb, 850mg, 1000mg, 1250mg twice daily will be tested. In Phase ll, the recommended phase ll dose (RP2D) in phase lb twice daily on day 1 to 14 followed by 7 days off Primary outcome(s): PFS, Progression Free Survival

DISEASE(S): Neoplasms

PROVIDER: 2513615 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR